

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850 UNITED STATES Phone: +1-888-267-4436 Fax: +1-301-340-8606

techsupport@origene.com

## OriGene Technologies GmbH

32052 Herford GERMANY Phone: +49-5221-34606-0 Fax: +49-5221-34606-11 info-de@origene.com

Schillerstr. 5

## AP55922PU-S Polyclonal Antibody to BCR pTyr360 - Aff - Purified

Alternate names: BCR1, Breakpoint cluster region protein, D22S11, NY-REN-26, Renal carcinoma antigen

NY-REN-26

Quantity:  $50 \mu g$ Concentration: 1.0 mg/ml

**Background:** GTPase-activating protein for RAC1 and CDC42. Promotes the exchange of RAC or

CDC42-bound GDP by GTP, thereby activating them. Displays serine/threonine kinase

activity.

Uniprot ID: P11274

NCBI: NP 004318.3

GeneID: 613
Host: Rabbit

Immunogen: Peptide sequence around phosphorylation site of tyrosine 360 (T-T-Y(p)-R-M) derived

from Human Bcr (KLH-conjugated)

Format: State: Liquid Ig fraction

Purification: Affinity chromatography using epitope-specific peptide

Buffer System: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH

7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol

**Applications:** Western blot: 1:500~1:1000.

Other applications not tested. Optimal dilutions are dependent on conditions and

should be determined by the user.

Molecular Weight: 142 kDa

Specificity: The antibody detects endogenous level of Bcr only when phosphorylated at tyrosine

360.

Species Reactivity: Tested: Human, Mouse

Storage: Upon receipt, store undiluted (in aliquots) at -20°C.

Avoid repeated freezing and thawing. Shelf life: one year from despatch.

General Readings: 1. Perazzona B, Lin H, Sun T, Wang Y, Arlinghaus R. Kinase domain mutants of Bcr

enhance Bcr-Abl oncogenic effects. Oncogene. 2008 Apr 3;27(15):2208-14. Epub 2007

Oct 15. PubMed PMID: 17934518.

2. Sun T, Campbell M, Gordon W, Arlinghaus RB. Preparation and application of antibodies to phosphoamino acid sequences. Biopolymers. 2001;60(1):61-75.

PubMed PMID: 11376433.

3. Wu Y, Liu J, Arlinghaus RB. Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase. Oncogene. 1998 Jan 8;16(1):141-6.

PubMed PMID: 9467953.



**Pictures:** 

Western blot analysis of extracts from COS7 tissue using Bcr (Phospho-Tyr360) antibody AP55922PU-N.The lane on the right is treated with the antigen-specific peptide.

